�The 2008 Frost & Sullivan European Transdermal Drug Delivery Product Innovation Award is conferred on Israel-based TransPharma Medical Ltd. in recognition of its forward-looking ViaDerm do drugs delivery system. The company's two flagship drug product development programs - ViaDerm hPTH (1-34) for the treatment of osteoporosis and ViaDerm-hGH for the treatment of human growth hormone deficiency - both in phase 2 of clinical development.
The unique ViaDerm system solution allows for low-cost, patient-friendly transdermal delivery of a wide mixture of drugs from a patch. Suitable for nursing home use, the ViaDerm system employs a re-usable battery-operated handheld electronic device in combination with a bandage containing the drug.
"The basis of the ViaDerm device is TransPharma's proprietorship RF-MicroChannel technology which is applied to create an array of microscopic pores in the outer skin surface, facilitating the systemic delivery of drugs," explains Frost & Sullivan Research Analyst Sylvia Miriyam Findlay. "The pores are created rapidly with no annoyance or psychic trauma to the skin. The device can be applied to all skin types and is fully controlled by a unique feedback mechanism that ensures precise and consistent drug delivery."
The RF-MicroChannels are large enough to enable the delivery of high molecular weight molecules and ar open up to 24 hours, thus allowing protracted systemic livery of a wide chain of mountains of dose molecules, including biologics, which are presently available mainly by shot. The ViaDerm system offers patients an administration method that avoids the need for injections, thereby increasing compliance and safety.
TransPharma Medical aims to have the charles Herbert Best solutions for unmet needs in transcutaneous drug pitch. It has attempted to meet the challenge of delivering large peptide and proteins by introducing the dry Printed Patch to complement its innovative RF-MicroChannel technology. The printed dapple uses the dry variety of the drug, thereby increasing stability and ledge life at room temperature.
"TransPharma Medical has invariably worked to spread its novel engineering for transcutaneous drug delivery in healing areas such as hormone, pain, osteoporosis and diabetes," adds Findlay. "Its application can cover a wide range of therapeutic molecules like hPTH, hGH, GLP-1 analogues, Granisetron, Calcitonine, Testosterone, Diclofenac, and more."
The company has sought to forge productive partnerships with pharmaceutical and biotechnology companies, which will maximise the synergy betwixt its innovative technology and pharmaceutical companies' pipelines. Accordingly, TransPharma Medical has a strategic coaction with Elli Lilly for the development and commercialisation of ViaDerm-hPTH (1-34) for the intervention of osteoporosis. The merchandise, currently in Phase 2 testing, is administered transdermally and thus can enable patients to manage their disease while eliminating the need for daily sore injections.
The Frost & Sullivan Award for Product Innovation is presented to the company that has demonstrated excellence in young products and technologies inside their diligence. The recipient company has shown excogitation by launch a broad line of emerging products and technologies.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding accomplishment and superior performance in areas such as leadership, technological institution, customer table service, and strategical product evolution. Industry analysts compare market participants and measure functioning through in-depth interviews, analysis, and all-encompassing secondary research in order to identify best practices in the industry.
About TransPharma Medical
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology. TransPharma aims to germinate multiple drug products through strategic partnerships with in the lead pharmaceutical companies and through independent product development. For more entropy, visit the Company's site at hTTP://www.transpharma-medical.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership� authorise clients to create a growth-focused culture that generates, evaluates and implements efficient growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global thousand companies, emerging businesses and the investment community from more than 30 offices on six continents. For more selective information about Frost & Sullivan's Growth Partnerships, visit hTTP://www.frost.com.
Frost & Sullivan
More info
